Market Capitalization (Millions $) |
2,817 |
Shares
Outstanding (Millions) |
117 |
Employees |
267 |
Revenues (TTM) (Millions $) |
140 |
Net Income (TTM) (Millions $) |
-13 |
Cash Flow (TTM) (Millions $) |
0 |
Capital Exp. (TTM) (Millions $) |
7 |
Olink Holding Ab Publ
Olink Holding AB publ is a publicly traded life science company based in Uppsala, Sweden. The company specializes in developing high-quality protein analysis technology that enables researchers and clinicians to analyze proteomic data within complex biological samples in a reliable and efficient manner. The company's patented technology, known as Proximity Extension Assay (PEA), allows for the measurement of large numbers of proteins in small sample volumes, with high sensitivity and specificity. Olink's technology is primarily used by researchers in the fields of biomarker discovery, drug development, and clinical diagnostics. The company's products include a range of panels of validated biomarker assays, which can be used to measure protein biomarkers in various disease areas, including cancer, cardiovascular disease, and inflammation. Olink was founded in 2004 and has since grown to become a leading provider of cutting-edge protein biomarker analysis technology. The company is publicly traded on the Nasdaq Stockholm exchange under the ticker symbol OLK. The company's mission is to enable precision medicine by providing researchers and doctors with the tools they need to develop better treatments and diagnostic tests for a wide range of diseases.
Company Address: Uppsala Science Park Uppsala 75 MA
Company Phone Number: 393-3933 Stock Exchange / Ticker: NASDAQ OLK
OLK is expected to report next financial results on March 26, 2024. |
|
|